Pharmaceutical Sector

Roche to Continue With Phase 3 Studies of TDM1 Despite FDA’s Disapproval

Trastuzumab-DM1 (T-DM1), a drug developed by Roche Holding AG, Swiss drug manufacturer, which is the first of its kind treatment that can contract tumours in HER2-positive breast cancer patients, is seeking approval from the Food and Drug Administration (FDA).

The Company submitted its application, along with the drug’s results from its Phase 2 trials to FDA, last month. Meanwhile, the phase 3 trials of the drug i.e. the first conjugated monoclonal antibody have been going on.


ProStrakan Positive Over its Latest Drug Patch

Pharmaceuticals Company ProStrakanis has a lot of hopes adhered to its anti-vomiting patch that it expects to starts retailing before the year-end. The firm speculates to fetch sales of up to $100 million (£64m) in the United States for its new patch.

However, the Company fears that its new patch may have the same destiny as that of Abstral in America.

The drug, which is already being retailed in Europe, had to face delay following the US Food & Drug Administration ruling of a three month extension in the review of the medicine.


Extended Treatment with Hepatitis C Drug Proved Optimistic, Informs Vertex

Vertex Pharma Inc. on Tuesday informed that one of the studies depicted that extended treatment with hepatitis C drug candidate, telaprevir, helped in fetching positive results for some patients.

The pharma firm said that patients, quite quickly responded to treatment after they had been given telaprevir that showed better results after 24 weeks of the given therapy. But it also said that there were no other benefits at extending the therapy to a term of 48 weeks.


Genzyme to Negotiate with Sanofi for its Takeover

Further negotiations will be carried out by the Genzyme Corp., a world renowned maker of medicines for genetic diseases with French drug maker Sanofi-Aventis SA, on the proposal of acquisition offered by the latter, as told by some sources.

Yesterday, the two parties met to discuss their plan and proceedings.

The people related with the matter told that the executives of Genzyme Corp. want to have talks with Sanofi to revise the offer to $80 per share from an offer of $67 to $70 a share.


Charles River Drops its Acquisition Deal

Charles River Laboratories International Inc. is reported to have abandoned its plans to acquire WuXi PharmaTech Inc., the Chinese drug testing Company under a deal worth $1.6 billion. The decision made by the Company is cited to be triggered by the agitation exhibited by its shareholders.

The Company dealing with laboratory rodents and facilitating animal testing for the pharmaceutical industry was in plans to widen its footprints by the acquisition deal, deemed to be the largest in the firm’s 63-year history.



Subscribe to RSS - Pharmaceutical Sector